Menu | Pharmacogenetics

References

1. Haga SB, Burke W. Using pharmacogenetics to improve drug safety and efficacy.
   JAMA. 2004; 291:2869-2871.
2. Goldstein DB, Tate SK, Sisodiya SM. Pharmacogenetics goes genomic. Nat Rev
   Genet. 2003; 4:937-947.
3. US National Archives & Records Administration. 21 CFR Part 320.
   Bioavailability and bioequivalence requirements. §320.33. Criteria and evidence to
   assess actual or potential bioequivalence problems. April 1, 2003.
4. Bukaveckas BL. Adding pharmacogenetics to the clinical laboratory: Narrow
   therapeutic index medications as a place to start. Arch Pathol Lab Med. 2004 Dec;
   128(12):1330-1333.
5. Blue Cross Blue Shield Association. Special report: Genotyping for
   cytochrome P450 polymorphisms to determine drug-metabolizer status.
   Technology Assessment Program. 2004; 19(9):1-34.
6. Human Cytochrome P450 (CYP) Allele Nomenclature Committee.
   www.imm.ki.se/CYPalleles. Cited: January 10, 2005.
7. American College of Clinical Pharmacology. Pharmacogenomics:
   Applications to Patient Care. AACP, Kansas City, Mo: ACCP;
   2004:262,263,290.
8. Cytochrome P450 Drug Interaction Table. medicine.iupui.edu/
   flockhart/ Cited: February 22, 2005.
9. Fishbain DA, Fishbain D, Lewis J, et al. Genetic testing for enzymes
   of drug metabolism: Does it have clinical utility for pain medicine at the
   present time? A structural review. Pain Med. 2005; 5(1):81-93.
10. Adcock DM, et al. Effect of Polymorphisms in the Cytochrome P450 CYP2C9
    Gene on Warfarin Anticoagulation. Arch Pathol Lab Med. 2004; 128:1360-1363.
11. American College of Clinical Pharmacy. Pharmacogenomics: Applications to
    Patient Care. Kansas City, Mo: ACCP; 2004.
12. Proceedings from FDA Clinical Pharmacology Subcommittee, November 3-4,
    2004. (http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004 4079B1_03_Topic1-TabA.pdf)
13. Innocenti F, Undevia SD, Iyer L, et al. Genetic variants in the UDP
    glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan. J Clin Oncol. 2004; 22:1382-1388.
14. Lim W-T, McLeod HL. Should screening for DPD deficiency be mandatory
    before 5-FU exposure? [Editorial] Onkologie. 2004; 27:531-533.